风湿免疫科

订阅

MedSci主页 / 所有栏目 / 风湿免疫科

FDA批准Xembify治疗原发性免疫缺陷

2019-07-05 不详 m

Xembify原发性免疫缺陷免疫球蛋白
关注

Grifols是一家全球领先的血浆衍生药物生产商，近日宣布，其新的20％皮下免疫球蛋白Xembify®已获得美国食品和药品监督管理局（FDA）的批准用于治疗原发性免疫缺陷。

Grifols是一家全球领先的血浆衍生药物生产商，近日宣布，其新的20％皮下免疫球蛋白Xembify®已获得美国食品和药品监督管理局（FDA）的批准用于治疗原发性免疫缺陷。Grifols商业生物科学部总裁Joel Abelson表示：“这项批准可以使我们更好地服务于患有原发性免疫缺陷的个体，加强了Grifols对患者和医疗保健专业人员的长期承诺”。该公司计划在2019年第四季度在美国推出Xembify®，并正在与医疗机构合作，以获得加拿大、欧洲和其他市场的批准。

原发性免疫缺陷疾病是指主要由免疫系统遗传缺陷引起的疾病。已有多种单发性缺陷和联合缺陷性疾病被报道，包括体液免疫缺陷，严重联合免疫缺陷，以及由吞噬缺陷和补体缺陷引起的疾病。


原始出处：

http://www.firstwordpharma.com/node/1651323#axzz5slCedqVw

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1846796, encodeId=d4331846e9605, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Jun 04 05:04:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707510, encodeId=31a51e075100b, content=<a href='/topic/show?id=1e7618813ad' target=_blank style='color:#2F92EE;'>#Xembify#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18813, encryptionId=1e7618813ad, topicName=Xembify)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1cd31427467, createdName=ms306040998833292, createdTime=Wed Jul 31 01:04:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839702, encodeId=08501839e028f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jul 26 11:04:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056754, encodeId=6b042056e54f4, content=<a href='/topic/show?id=19983e04485' target=_blank style='color:#2F92EE;'>#原发性免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37044, encryptionId=19983e04485, topicName=原发性免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Fri Aug 02 14:04:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488991, encodeId=460d148899177, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Sun Jul 07 00:04:00 CST 2019, time=2019-07-07, status=1, ipAttribution=)]
    2020-06-04 jiyangfei

    #原发性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1846796, encodeId=d4331846e9605, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Jun 04 05:04:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707510, encodeId=31a51e075100b, content=<a href='/topic/show?id=1e7618813ad' target=_blank style='color:#2F92EE;'>#Xembify#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18813, encryptionId=1e7618813ad, topicName=Xembify)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1cd31427467, createdName=ms306040998833292, createdTime=Wed Jul 31 01:04:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839702, encodeId=08501839e028f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jul 26 11:04:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056754, encodeId=6b042056e54f4, content=<a href='/topic/show?id=19983e04485' target=_blank style='color:#2F92EE;'>#原发性免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37044, encryptionId=19983e04485, topicName=原发性免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Fri Aug 02 14:04:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488991, encodeId=460d148899177, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Sun Jul 07 00:04:00 CST 2019, time=2019-07-07, status=1, ipAttribution=)]
    2019-07-31 ms306040998833292

    #Xembify#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1846796, encodeId=d4331846e9605, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Jun 04 05:04:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707510, encodeId=31a51e075100b, content=<a href='/topic/show?id=1e7618813ad' target=_blank style='color:#2F92EE;'>#Xembify#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18813, encryptionId=1e7618813ad, topicName=Xembify)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1cd31427467, createdName=ms306040998833292, createdTime=Wed Jul 31 01:04:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839702, encodeId=08501839e028f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jul 26 11:04:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056754, encodeId=6b042056e54f4, content=<a href='/topic/show?id=19983e04485' target=_blank style='color:#2F92EE;'>#原发性免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37044, encryptionId=19983e04485, topicName=原发性免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Fri Aug 02 14:04:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488991, encodeId=460d148899177, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Sun Jul 07 00:04:00 CST 2019, time=2019-07-07, status=1, ipAttribution=)]
    2019-07-26 bugit

    #FDA批准#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1846796, encodeId=d4331846e9605, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Jun 04 05:04:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707510, encodeId=31a51e075100b, content=<a href='/topic/show?id=1e7618813ad' target=_blank style='color:#2F92EE;'>#Xembify#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18813, encryptionId=1e7618813ad, topicName=Xembify)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1cd31427467, createdName=ms306040998833292, createdTime=Wed Jul 31 01:04:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839702, encodeId=08501839e028f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jul 26 11:04:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056754, encodeId=6b042056e54f4, content=<a href='/topic/show?id=19983e04485' target=_blank style='color:#2F92EE;'>#原发性免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37044, encryptionId=19983e04485, topicName=原发性免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Fri Aug 02 14:04:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488991, encodeId=460d148899177, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Sun Jul 07 00:04:00 CST 2019, time=2019-07-07, status=1, ipAttribution=)]
    2019-08-02 xuqianhua

    #原发性免疫缺陷#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1846796, encodeId=d4331846e9605, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Thu Jun 04 05:04:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707510, encodeId=31a51e075100b, content=<a href='/topic/show?id=1e7618813ad' target=_blank style='color:#2F92EE;'>#Xembify#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18813, encryptionId=1e7618813ad, topicName=Xembify)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1cd31427467, createdName=ms306040998833292, createdTime=Wed Jul 31 01:04:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839702, encodeId=08501839e028f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri Jul 26 11:04:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056754, encodeId=6b042056e54f4, content=<a href='/topic/show?id=19983e04485' target=_blank style='color:#2F92EE;'>#原发性免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37044, encryptionId=19983e04485, topicName=原发性免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Fri Aug 02 14:04:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488991, encodeId=460d148899177, content=<a href='/topic/show?id=7df32913871' target=_blank style='color:#2F92EE;'>#免疫缺陷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29138, encryptionId=7df32913871, topicName=免疫缺陷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631b8488299, createdName=rebeccajiejie, createdTime=Sun Jul 07 00:04:00 CST 2019, time=2019-07-07, status=1, ipAttribution=)]
    2019-07-07 rebeccajiejie

    #免疫缺陷#

    0